{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:04:25Z","timestamp":1789790665049,"version":"4.0.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.039","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:47:47Z","timestamp":1787464067000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T and GvHD: Have We Engineered GvHD Out of Allogeneic CAR\u2011T Therapy?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7550-213X","authenticated-orcid":false,"given":"Nabeel","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.039_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1585556","article-title":"Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"16","author":"Biederst\u00e4dt","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.08.039_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.08.039_bib0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.08.039_bib0004","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.039_bib0005","article-title":"Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): updated Results from the antler phase 1 clinical trial","volume":"32","author":"Hamadani","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.039_bib0006","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2026020123","article-title":"Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed\/refractory B-cell non-Hodgkin lymphoma","author":"McGuirk","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.039_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation\u2014successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.08.039_bib0008","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/cancers18101634","article-title":"Evaluation of efficacy and safety of chimeric antigen receptor-natural killer (CAR-NK) cells in breast cancer: a systematic review and meta-analysis","volume":"18","author":"Ahmed","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.08.039_bib0009","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2026.08.039_bib0010","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.stem.2025.07.009","article-title":"Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease","volume":"32","author":"Hu","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:37:58Z","timestamp":1789789078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"alternative-id":["S2666636726006809"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.039","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T and GvHD: Have We Engineered GvHD Out of Allogeneic CAR\u2011T Therapy?","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}